Teva Pharmaceutical Industries Free Cash Flow 2010-2022 | TEVA
Teva Pharmaceutical Industries annual/quarterly free cash flow history and growth rate from 2010 to 2022. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Teva Pharmaceutical Industries free cash flow for the quarter ending December 31, 2022 was 1,110.00, a year-over-year.
- Teva Pharmaceutical Industries free cash flow for the twelve months ending December 31, 2022 was , a year-over-year.
- Teva Pharmaceutical Industries annual free cash flow for 2022 was $1.11B, a 102.93% increase from 2021.
- Teva Pharmaceutical Industries annual free cash flow for 2021 was $0.547B, a 22.41% decline from 2020.
- Teva Pharmaceutical Industries annual free cash flow for 2020 was $0.705B, a 24.56% increase from 2019.
| Teva Pharmaceutical Industries Annual Free Cash Flow |
| 2022 |
1,110.00 |
| 2021 |
547.00 |
| 2020 |
705.00 |
| 2019 |
566.00 |
| 2018 |
2,685.00 |
| 2017 |
4,828.00 |
| 2016 |
6,326.00 |
| 2015 |
5,294.00 |
| 2014 |
4,394.00 |
| 2013 |
2,393.00 |
| 2012 |
3,732.00 |
| 2011 |
3,360.00 |
| 2010 |
4,126.00 |
| 2009 |
2,925.00 |
| Teva Pharmaceutical Industries Quarterly Free Cash Flow |
| 2022-12-31 |
1,110.00 |
| 2022-09-30 |
256.00 |
| 2022-06-30 |
-167.00 |
| 2022-03-31 |
-181.00 |
| 2021-12-31 |
547.00 |
| 2021-09-30 |
202.00 |
| 2021-06-30 |
-196.00 |
| 2021-03-31 |
-417.00 |
| 2020-12-31 |
705.00 |
| 2020-09-30 |
537.00 |
| 2020-06-30 |
364.00 |
| 2020-03-31 |
183.00 |
| 2019-12-31 |
566.00 |
| 2019-09-30 |
-29.00 |
| 2019-06-30 |
-218.00 |
| 2019-03-31 |
-2.00 |
| 2018-12-31 |
2,685.00 |
| 2018-09-30 |
1,641.00 |
| 2018-06-30 |
2,200.00 |
| 2018-03-31 |
2,157.00 |
| 2017-12-31 |
4,828.00 |
| 2017-09-30 |
2,366.00 |
| 2017-06-30 |
1,661.00 |
| 2017-03-31 |
1,346.00 |
| 2016-12-31 |
6,326.00 |
| 2016-09-30 |
5,032.00 |
| 2016-06-30 |
2,031.00 |
| 2016-03-31 |
1,206.00 |
| 2015-12-31 |
5,294.00 |
| 2015-09-30 |
3,911.00 |
| 2015-06-30 |
2,915.00 |
| 2015-03-31 |
1,251.00 |
| 2014-12-31 |
4,394.00 |
| 2014-09-30 |
2,903.00 |
| 2014-06-30 |
1,676.00 |
| 2014-03-31 |
691.00 |
| 2013-12-31 |
2,393.00 |
| 2013-09-30 |
1,877.00 |
| 2013-06-30 |
1,638.00 |
| 2013-03-31 |
981.00 |
| 2012-12-31 |
3,732.00 |
| 2012-09-30 |
2,418.00 |
| 2012-06-30 |
1,552.00 |
| 2012-03-31 |
608.00 |
| 2011-12-31 |
3,360.00 |
| 2011-09-30 |
2,145.00 |
| 2011-06-30 |
1,905.00 |
| 2011-03-31 |
751.00 |
| 2010-12-31 |
3,426.00 |
| 2010-09-30 |
3,217.00 |
| 2010-06-30 |
2,124.00 |
| 2010-03-31 |
789.00 |
| 2009-12-31 |
2,654.00 |
| 2009-09-30 |
1,909.00 |
| 2009-06-30 |
1,080.00 |
| 2009-03-31 |
573.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$9.698B |
$14.925B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
